Stocks That Hit 52-Week Lows On Friday
During Friday's session, 198 companies made new 52-week lows.
New Energy Lands as Hottest Category Among Chinese Concept Stocks in 2021 – Bamboo Works Special Report
Investors kept a close look at China’s solar and wind power stocks last year, but were least interested in the hobbled education sector
By Bamboo Works team
63 Biggest Movers From Yesterday
Gainers
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares surged 93.2% to close at $1.70 on Thursday. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors.
Mid-Day Market Update: Crude Oil Rises 0.5%; Integrated Media Technology Shares Jump
Midway through trading Thursday, the Dow traded up 0.04% to 36,504.54 while the NASDAQ rose 0.59% to 15,859.87. The S&P also rose, gaining 0.14% to 4,799.86.
75 Biggest Movers From Yesterday
Gainers
Society Pass Incorporated (NASDAQ: SOPA) surged 436.7% to settle at $48.30 on Tuesday after the company priced its IPO at $9 per share.
58 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Dover Motorsports, Inc. (NYSE: DVD) shares climbed 60.3% to $3.59 after Speedway Motorsports announced it will acquire the company for $3.61 per share in cash.
32 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
Dover Motorsports, Inc. (NYSE: DVD) rose 57% to $3.58 in pre-market trading.
Yalla Group Q3 EPS $0.18 Down From $0.20 YoY, Sales $71.30M Beat $69.90M Estimate
Yalla Group (NYSE:YALA) reported quarterly earnings of $0.18 per share. This is a 10 percent decrease over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $71.30
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
85 Biggest Movers From Yesterday
Gainers
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers.